BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Epogen epoetin alfa regulatory update

During a conference call last week, Amgen said it is in discussions with FDA to clarify the hemoglobin targets for chronic kidney disease (CKD) patients in labels for erythropoiesis-stimulating agents (ESAs). The company said FDA is "anxious to get away from the...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >